Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Andreea Ioana Paroşanu"'
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1111 (2024)
The management of renal cell carcinoma (RCC) has been revolutionized over the past two decades with several practice-changing treatments. Treatment for RCC often requires a multimodal approach: Local treatment, such as surgery or ablation, is typical
Externí odkaz:
https://doaj.org/article/8545389781424c5cbc4e4d7a1e500a72
Autor:
Catalin Baston, Andreea Ioana Parosanu, Mihaela Mihai, Oana Moldoveanu, Ioana Miruna Stanciu, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 14, Iss 5, p 553 (2024)
Tumor-to-tumor metastasis (TTM) is a rare phenomenon documented in patients with multiple primary cancers. This condition is defined as a metastasis between two true primary tumors. The most frequently reported recipient tumor is renal cell carcinoma
Externí odkaz:
https://doaj.org/article/d23d71780ef64a5daf0ea9cecec5fa48
Autor:
Andreea Ioana Parosanu, Cristina Florina Pirlog, Cristina Orlov Slavu, Ioana Miruna Stanciu, Horia-Teodor Cotan, Radu Constantin Vrabie, Ana-Maria Popa, Mihaela Olaru, Cristian Iaciu, Lucian Ioan Bratu, Ionut Florian Baicoianu, Oana Moldoveanu, Catalin Baston, Cornelia Nițipir
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 2457-2464 (2023)
Background: Metastatic renal cell carcinoma (mRCC) is an aggressive cancer characterised by an increased recurrence rate and an inadequate response to treatment. This study aimed to investigate the importance of the neutrophil-to-lymphocyte ratio (NL
Externí odkaz:
https://doaj.org/article/0895789e72fe44cf8e12d3a27289df91
Autor:
Cristina-Florina Pîrlog, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Iaciu, Irina Niță, Pompilia Moțatu, Cotan Horia, Loredana Sabina Cornelia Manolescu, Cornelia Nițipir
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9428-9436 (2022)
Immune-checkpoint inhibitors (ICIs) are the most effective treatments nowadays. Nivolumab was the second ICI used for treating solid tumors with amazing results. Patients treated with Nivolumab may react differently to this treatment. Some people tol
Externí odkaz:
https://doaj.org/article/af369dd6c61d480da3673f8b2e269ddf
Publikováno v:
Biomolecules, Vol 13, Iss 9, p 1422 (2023)
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer over the last decade. These inhibitors are currently
Externí odkaz:
https://doaj.org/article/ac584e7b9e3b4b2dafbea08cbdbce074
Autor:
Andreea Ioana Parosanu, Catalin Baston, Ioana Miruna Stanciu, Cristina Florina Parlog, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 13, Iss 14, p 2430 (2023)
Background: Over the past few years, significant advancements have been achieved in the front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will eventually encounter disease progression during this front-line trea
Externí odkaz:
https://doaj.org/article/d1dcada7c08b4a64b8bae88dbf26557f
Autor:
Cristina-Florina Pîrlog, Raluca Costache, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Iaciu, Irina Niță, Pompilia Moțatu, Horia Teodor Cotan, Alexandru Vlad Oprița, Daniel Costache, Loredana Sabina Cornelia Manolescu, Cornelia Nițipir
Publikováno v:
Diagnostics, Vol 13, Iss 11, p 1892 (2023)
Background: Lung cancer (LC) is the first and most lethal cancer in the world; identifying new methods to treat it, such as immune checkpoint inhibitors (ICIs), is needed. ICIs treatment is very effective, but it comes bundled with a series of immune
Externí odkaz:
https://doaj.org/article/71eedd2c07834566a6a2ac720251c1ae
Autor:
Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Medicina, Vol 59, Iss 4, p 696 (2023)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Followi
Externí odkaz:
https://doaj.org/article/3937aff8b0fd4bc7a9b4c3be4d446f1b
Autor:
Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 13, Iss 5, p 987 (2023)
The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in associati
Externí odkaz:
https://doaj.org/article/6c9da4fa657d4d3eb1982d2cad5f926e
Autor:
Cornelia Niţipir, Irina Alexandra Răduţ, Andreea Ioana Paroşanu, Iulian Slavu, Maria Cristina Orlov-Slavu, Raluca Tulin, Anca Oprescu-Macovei, Ioana Creţu, Bogdan Creţu, Răzvan Adrian Stoica
Publikováno v:
Romanian Journal of Orthopaedic Surgery and Traumatology. 5:28-34
Introduction: In most patients, metastatic breast cancer (MBC) is incurable. Consequently, the goal in this setting is life prolongation and quality of life improvement, although possible long-term effects of anticancer treatment need to be considere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8427057f7fa1a8e0cdc960d33a58bdf6
https://doi.org/10.2478/rojost-2022-0006
https://doi.org/10.2478/rojost-2022-0006